Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for certain blood cancers and is prescribed for adult patients with specific disease subtypes.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide Sandoz is used in hematologic malignancies that respond to immunomodulatory therapy. - Multiple myeloma: improves progression‑free survival and overall response rates in eligible patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias. - Mantle cell lymphoma: contributes to disease control when combined with other agents.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Hepatic failure: significant liver enzyme elevation and dysfunction.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thromboembolic risk: consider prophylactic anticoagulation when indicated. - Evaluate renal and hepatic function: adjust use based on organ performance. - Avoid use in pregnancy: teratogenic potential requires strict contraception. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic exposure. - Anticoagulants (e.g., warfarin): increased bleeding risk. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase drug levels. - NSAIDs: additive risk of neutropenia and gastrointestinal bleeding. - Diuretics: potential electrolyte disturbances requiring monitoring.